In vivo activity of anprocide alone, and in vitro activity in combination with conventional antibiotics against Staphylococcus aureus and Staphylococcus epidermidis biofilms

Pettit, Robin K.; Weber, Christine A.; Lawrence, Stacey B.; Pettit, George R.; Kean, Melissa J.; Cage, Gary D.

doi:10.1099/jmm.0.008268-0

Cited by 8 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other combinations of antibiotics and antifungal drugs exhibiting synergistic activity include: (1) aminoglycosides and fosfomycin against P. aeruginosa biofilm in a rat model (Cai et al , 2009); (2) anprocide and bacitracin or oxacillin against S. aureus and S. epidermidis biofilms in vitro (Pettit et al , 2009); and (3) amphotericin B, caspofungin or fluconazole in combination with a high‐dose doxycycline against C. albicans biofilms in vitro (Miceli et al , 2009).…”

Section: Do We Need Novel Antibiofilm Biomaterials New Synergisticalmentioning

confidence: 99%

Prevention and control of biofilm-based medical-device-related infections

Francolini

Donelli

2010

FEMS Immunol Med Microbiol

408

312

View full text Add to dashboard Cite

Biofilms play a pivotal role in healthcare-associated infections, especially those related to the implant of medical devices, such as intravascular catheters, urinary catheters and orthopaedic implants. This paper reviews the most successful approaches for the control and prevention of these infections as well as promising perspectives for the development of novel devices refractory to microbial adhesion, colonization and biofilm formation.

show abstract

Section: Do We Need Novel Antibiofilm Biomaterials New Synergisticalmentioning

confidence: 99%

Prevention and control of biofilm-based medical-device-related infections

Francolini

Donelli

2010

FEMS Immunol Med Microbiol

408

312

View full text Add to dashboard Cite

show abstract

“…Therefore, drug combinations are often used to overcome biofilm formation, especially antibiotic-antibiotic combinations (43)(44)(45). Despite a favorable anti-biofilm effect, the combination of antibiotics can result in the generation of drug resistant bacteria, and enhance the toxicity to humans.…”

Section: Discussionmentioning

confidence: 99%

Hyperoside inhibits biofilm formation of Pseudomonas aeruginosa

Sun

Feng

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Pseudomonas aeruginosa (P. aeruginosa) is a common pathogen in hospital-acquired infection and is readily able to form biofilms. Due to its high antibiotic resistance, traditional antibacterial treatments exert a limited effect on P. aeruginosa biofilm infections. It has been indicated that hyperoside inhibits P. aeruginosa PAO1 (PAO1) biofilm formation without affecting growth. Therefore, the current study examined the biofilm formation and quorum sensing (QS) system of PAO1 in the presence of hyperoside.Confocal laser scanning microscopy analysis demonstrated that hyperoside significantly inhibited biofilm formation. It was also observed that hyperoside inhibited twitching motility in addition to adhesion. Data from reverse transcription-quantitative polymerase chain reaction indicated that hyperoside inhibited the expression of lasR, lasI, rhlR and rhlI genes. These results suggest that the QS-inhibiting effect of hyperoside may lead to a reduction in biofilm formation. However, the precise mechanism of hyperoside on P. aeruginosa pathogenicity remains unclear and requires elucidation in additional studies. IntroductionPseudomonas aeruginosa (P. aeruginosa) is a common pathogen in hospital-acquired infections (1). Due to increasing multidrug resistance, P. aeruginosa infection is an increasingly common cause of mortality and morbidity (2). The mechanisms of antibiotic resistance in P. aeruginosa include the expression of multiple antibiotic modifying enzymes, antibiotic efflux pumps and acquisition of chromosomally or plasmid encoded antibiotic resistance genes. Additionally, chromosomal mutations and lower membrane permeability for the antibiotics also contribute to antibiotic resistance (3).P. aeruginosa is a biofilm-forming pathogen and is difficult to eradicate due to its high antibiotic resistance and the ability of the biofilm to evade the immune system (4-7). Quorum sensing (QS) is a system of stimuli and response correlated to population density. P. aeruginosa uses the QS system to coordinate gene expression according to the density of its local population. Thus, it can coordinate certain behaviors such as biofilm formation, virulence and antibiotic resistance. QS inhibitors (QSIs) are the most well reported alternative therapeutics that can be used to overcome the problem of increasing antibiotic resistance in P. aeruginosa. QSIs target the virulence of the organism and therefore are also termed antipathogenic drugs. The virulence of P. aeruginosa depends on its cell-to-cell communication system, or QS system that uses diffusible signaling molecules that accumulate with increasing cell density and allows P. aeruginosa to trigger coordinated responses and achieve outcomes that would otherwise remain impossible to achieve by individual bacterium (8). Previous studies have demonstrated that traditional treatments for bacteria exert some effect on biofilm infections (9,10). Therefore, the effects of constituents from marine organisms, traditional Chinese herbs and plants (11-13) on biofilm infe...

show abstract

“…Researchers continue to try various combination schemes to eliminate biofilms through synergistic effects and are also trying sequential/alternate therapies and high-dose topical treatments (Akturk et al, 2019 ). Most studies have focused on common multidrug-resistant pathogens that cause nosocomial infections, such as E. coli, P. aeruginosa, S. aureus , coagulase negative staphylococci, and C. albicans (Cai et al, 2009 ; Pettit et al, 2009 ; Sarkar et al, 2014 ; Wang Y. et al, 2014 ; Ahmed et al, 2019 ). Many studies have identified the synergistic activities of traditional antibiotics not only in vitro but also in vivo (Cai et al, 2009 ; Pettit et al, 2009 ).…”

Section: Strategies Against Microbial Biofilmsmentioning

confidence: 99%

“…Most studies have focused on common multidrug-resistant pathogens that cause nosocomial infections, such as E. coli, P. aeruginosa, S. aureus , coagulase negative staphylococci, and C. albicans (Cai et al, 2009 ; Pettit et al, 2009 ; Sarkar et al, 2014 ; Wang Y. et al, 2014 ; Ahmed et al, 2019 ). Many studies have identified the synergistic activities of traditional antibiotics not only in vitro but also in vivo (Cai et al, 2009 ; Pettit et al, 2009 ). Multiple factors need to be considered, such as the susceptibility, targets of the antibiotics, permeability, and PK/PD in the biofilm of the antibiotics, when a combination therapy is used (Cernohorsk and Votava, 2008 ; Dales et al, 2009 ; Rose and Poppens, 2009 ).…”

Section: Strategies Against Microbial Biofilmsmentioning

confidence: 99%

Promising Therapeutic Strategies Against Microbial Biofilm Challenges

Zhang

Chen

et al. 2020

Front. Cell. Infect. Microbiol.

114

View full text Add to dashboard Cite

Biofilms are communities of microorganisms that are attached to a biological or abiotic surface and are surrounded by a self-produced extracellular matrix. Cells within a biofilm have intrinsic characteristics that are different from those of planktonic cells. Biofilm resistance to antimicrobial agents has drawn increasing attention. It is well-known that medical device-and tissue-associated biofilms may be the leading cause for the failure of antibiotic treatments and can cause many chronic infections. The eradication of biofilms is very challenging. Many researchers are working to address biofilm-related infections, and some novel strategies have been developed and identified as being effective and promising. Nevertheless, more preclinical studies and well-designed multicenter clinical trials are critically needed to evaluate the prospects of these strategies. Here, we review information about the mechanisms underlying the drug resistance of biofilms and discuss recent progress in alternative therapies and promising strategies against microbial biofilms. We also summarize the strengths and weaknesses of these strategies in detail.

show abstract

In vivo activity of anprocide alone, and in vitro activity in combination with conventional antibiotics against Staphylococcus aureus and Staphylococcus epidermidis biofilms

Cited by 8 publications

References 20 publications

Prevention and control of biofilm-based medical-device-related infections

Prevention and control of biofilm-based medical-device-related infections

Hyperoside inhibits biofilm formation of Pseudomonas aeruginosa

Promising Therapeutic Strategies Against Microbial Biofilm Challenges

Contact Info

Product

Resources

About